Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
December 31, 2015
RegMed’s close: the last day of trading expires
December 28, 2015
RegMed’s close: lower as traders cull any upside
December 22, 2015
RegMed’s close: pressured to the downside
December 21, 2015
RegMed’s close: flip, flop who has a drop of Santa Claus sentiment?
December 17, 2015
RegMed’s close: waiting for the “witch”
December 16, 2015
RegMed’s close: Stocks surge but, caution should be your middle name
December 15, 2015
RegMed’s close: my pattern analysis indicated the sector had to be UP
December 14, 2015
RegMed’s close: the sector opened strong to implode by the first half-hour
December 10, 2015
RegMed’s close: why close the barn door when the appreciation is leaving on its own
December 9, 2015
RegMed’s close: mired in disappointment
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.